Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Accumulated Expenses (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Accumulated Expenses for 8 consecutive years, with $700000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses fell 95.04% to $700000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $700000.0, a 95.04% decrease, with the full-year FY2024 number at $1.3 million, down 90.68% from a year prior.
  • Accumulated Expenses was $700000.0 for Q3 2025 at Whitehawk Therapeutics, down from $881000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $14.9 million in Q4 2022 to a low of $18487.0 in Q1 2021.
  • A 5-year average of $7.6 million and a median of $9.2 million in 2021 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 96.46% in 2021, then skyrocketed 5179.39% in 2022.
  • Whitehawk Therapeutics' Accumulated Expenses stood at $8.7 million in 2021, then skyrocketed by 71.46% to $14.9 million in 2022, then decreased by 4.13% to $14.3 million in 2023, then tumbled by 90.68% to $1.3 million in 2024, then tumbled by 47.49% to $700000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Accumulated Expenses are $700000.0 (Q3 2025), $881000.0 (Q2 2025), and $1.3 million (Q4 2024).